Lautaro Martinez ended a near two-month goal drought as Inter Milan closed to within one point of Serie A leaders Atalanta by sweeping aside Cagliari 3-0. Martinez had gone eight matches since last finding the back of the net against Venezia on November 3 but after Alessandro Bastoni opened the scoring in the 54th minute, the Argentina international struck in Sardinia. The Inter captain took his tally against Cagliari to 10 goals in as many games after 71 minutes before Hakan Calhanoglu capped an excellent night for the visitors from the penalty spot a few moments later. This moment >>> #ForzaInter #CagliariInter pic.twitter.com/aZwbAZvRVI — Inter ⭐⭐ (@Inter_en) December 28, 2024 Inter’s fifth-successive league victory led to them temporarily leapfrogging Atalanta, who reclaimed top spot but saw their lead cut to a single point following a 1-1 draw at Lazio. Gian Piero Gasperini’s side were grateful for a point in the end after falling behind to Fisayo Dele-Bashiru’s first-half strike, only drawing level with two minutes remaining thanks to Marco Brescianini. Lautaro Valenti’s last-gasp strike condemned rock-bottom Monza to a 10th defeat in 18 matches as Parma edged a 2-1 victory, while Genoa defeated Empoli by the same scoreline.UNC-Chapel Hill Researchers Discover the Youngest Transiting Planet
WESTFIELD — HVAC manufacturer Mestek Inc. has sued a Chinese company, saying the unrelated Shenzhen Mestek Electronics Co. is using the Mestek name and the Westfield company’s reputation to sell temperature and moisture sensing tools online. Westfield’s Mestek says the fan components it makes are for sale on the Chinese Mestek’s Amazon storefront next to electronic thermometers and sensors made by the Chinese company, according to a federal suit filed this week in the U.S. District Court in Springfield. The Chinese company’s Mestek products are also for sale on Chinese online marketplace Alibaba , on Amazon and elsewhere. Alibaba is based in China, but payment is accepted in U.S. dollars and shipping is available to the states, according to the suit. Westfield’s Mestek also said the fan components it makes are for sale on the Chinese Mestek’s Amazon storefront next to electronic thermometers and sensors made by the Chinese company, according to court papers. The suit includes examples of the Chinese Mestek using the name and similar logo. American Mestek says the Chinese company’s tools used to measure temperature, electricity or moisture are related to the heating, cooling, air handling and system control equipment it makes. Mestek says it’s been using the brand name “Mestek” for 40 years selling and promoting its line of heating, cooling, ventilating, metal forming machinery, architectural products, intelligent boiler controls, computer information systems and services and related products. But its corporate roots go back to1898. The suit says the Westfield Mestek discovered the Chinese company was using the name in October 2024 and later found out the Chinese firm had trademarked a similar logo to its own. Shenzhen Mestek Electronics first filed paperwork to register the trademark in 2017, according to the U.S. Patent and Trademark Office. The paperwork was renewed in 2022. Neither the Westfield Mestek nor its attorney, Kevin H. Vanderleeden of the Springfield-based intellectual property and patent firm Grogan, Truccillo & Vanderleeden. responded to calls for comment Thursday. The Chinese company didn’t respond to emails and has not filed a response to the suit, according to the docket. Suits like this one meant to protect an American company’s intellectual property from Chinese interlopers have become increasingly common, according to a 2023 piece in MIT Technology Review. The suits are also lucrative for the U.S. law firms to file them and collect damages. Stories by Jim Kinney
Way back in January, when the stink of a 5-7 season was still lingering on South Carolina, Shane Beamer held his first team meeting for the 2024 Gamecocks. He made a comment about a bowl game at the end of the season, how South Carolina was going to get back to the postseason after missing it for the first time in Beamer’s tenure. Right after the meeting, five-star freshman edge rusher Dylan Stewart — who might have been on campus for 48 hours — walked up to his new coach with a declaration. “Enough of this bowl stuff,” Beamer said Stewart told him. “We have higher expectations that that.” On Saturday afternoon in the bowels of Memorial Stadium, Beamer sat behind the podium after South Carolina’s 17-14 win over No. 12 Clemson , having earned the chance to make his case for the Gamecocks as a College Football Playoff team. “I do believe we deserve a spot in the 12-team playoff,” Beamer said. “I get it, the committee has a really tough job. They have to choose the 12 best teams. I get it, we’ve got three losses. “When you look at our strength of schedule (No. 15 in FBS), our wins on the road (4-1) in tough environments,” he continued, “we aren’t playing in front of 20,000 people like some teams do. We go into hostile environments every single week. Our only loss on the road is a two-point loss” at Alabama. The No. 15 Gamecocks (9-3) went into Saturday in the playoff picture but, per ESPN’s Playoff Predictor, had just a 58% chance of making the 12-team field with a win over Clemson (9-3). But then they actually beat the Tigers, defeating another ranked team to finish the season on a six-game winning streak. If the playoff is about finding the true top dozen teams, Beamer argued, how could South Carolina be left out? “If the committee’s job is to pick the 12 best teams,” Beamer said, “you tell me on selection Sunday, if South Carolina pops up in that bracket, I don’t know anyone that would be excited about playing this team the way we’re playing. That is what I judge it on.” Whether or not it will be a part of the selection committee’s decision when they choose the inaugural 12-team College Football Playoff field next Sunday, Beamer made a pretty convincing point. To look across college football is to see a bunch of mercurial teams. On Friday, Georgia needed eight overtimes to beat a 7-5 Georgia Tech team . Just as the Clemson-South Carolina game went final, Michigan (7-5) knocked off No. 2 Ohio State. And that all comes just a week after six teams ranked in the Top 16 lost. Yet, South Carolina just keeps winning. The Gamecocks have not faltered since Oct. 12 . While they do have three blemishes on their record — losses to LSU, Ole Miss and Alabama — there’s no truly ugly loss. “I don’t know if there is a hotter team in America than what we are,” Beamer said. “Six wins in a row, four over ranked opponents, on the road for two of them. Outside of the Alabama loss, this was the first close road game we had all season. “We are hot,” he added. “You want to be a team that is playing their best football at the end of the season. We sure are.” When is the next College Football Playoff rankings release? The next College Football Playoff show and Top 25 release is 7 p.m. Tuesday on ESPN. The final CFP selections and playoff bracket will be revealed at noon next Sunday, Dec. 8. This story was originally published November 30, 2024, 6:00 PM.
Pep Guardiola: If I can’t reverse Manchester City slide then I have to goWomen's surfing pioneer Phyllis O'Donnell honoured in Gold Coast paddle out
38th Annual Conference of OCS and National Seminar on “Advancements in Materials Chemistry” inaugurated in OUTRGophers soccer team literally dancing its way into the NCAA tournament second round
Toll Brothers, Inc. (NYSE:TOL) Stake Increased by Cerity Partners LLCMajor hockey tournaments, holiday shoppers bring big business to Ottawa
Pep Guardiola: If I can’t reverse Manchester City slide then I have to go
5 Phones Under Rs 20,000 For Gamers: Motorola, Samsung, iQOO, Nothing, And Redmi
Roivios Initiates Landmark Study to Demonstrate Safety and Efficacy of an Innovative Renal Assist Device for Cardiac Surgery Patients With Kidney Disease NASSAU, Bahamas , Dec. 19, 2024 /PRNewswire/ -- Roivios , a pioneering clinical-stage medical device company dedicated to revolutionizing kidney health, proudly announces that its research and development arm, 3ive Labs, has secured approval for an Investigational Device Exemption (IDE) from the FDA. This approval paves the way for a pivotal trial of the JuxtaFlow Renal Assist Device (RAD), marking a transformative step forward in enhancing outcomes for cardiac surgery patients with renal insufficiency. The GRADIENT ( G roundbreaking R enal A ssist D evice I ntervening to EN hance cardio T horacic surgery outcomes) trial is designed to address the critical need for renal support among cardiac surgery patients undergoing cardiopulmonary bypass (CPB). These patients often face increased risks of postoperative complications, such as worsening renal dysfunction, which can lead to extended ICU stays and increased mortality. "The GRADIENT Trial offers an invaluable opportunity to further explore renal support during cardiac surgery," said Dr. Evelio Rodriguez , a renowned heart surgeon at Ascension Saint Thomas in Nashville, TN , and the National Principal Investigator of the GRADIENT trial. "The JuxtaFlow device offers new hope for some of our most vulnerable patients." JuxtaFlow RAD is an innovative device designed to potentially improve kidney function during times of acute stress. By applying a gentle suction to the kidney's outlet, it aims to enhance blood filtration more efficiently. This groundbreaking approach was recognized with an FDA Breakthrough Device Designation in April. The GRADIENT study will be a prospective, multicenter, randomized, controlled, open-label trial that plans to enroll patients with renal insufficiency (eGFR 15-60 ml/min) undergoing elective or urgent cardiac surgery requiring CPB. The study seeks to evaluate the safety and effectiveness of the JuxtaFlow RAD to sustain or enhance renal function during and following CPB surgery. "Achieving Breakthrough Device Designation was instrumental in securing IDE approval," noted John Erbey , Chief Executive Officer at Roivios. "This initiative is the culmination of a decade of technological and clinical advancements in addressing kidney disease management challenges. Our ongoing dialogue with the FDA is paving the way for more effective management, empowering patients to thrive. We are eager to commence IDE enrollment and explore the JuxtaFlow RAD's potential to improve surgical outcomes and enhance patient quality of life." For more information about Roivios and the JuxtaFlow Renal Assist Device, please visit Roivios.com . About JuxtaFlow RAD The JuxtaFlow RAD is a pioneering investigational device set to transform kidney support therapy. Acknowledging the harmful effects of fluid accumulation and pressure on the kidneys, Roivios has advanced beyond traditional blood filtration methods that can further stress the kidneys. By applying mild, controlled negative pressure within the kidney's collecting system, the device has the potential to maintain and improve filtration and support recovery. This novel approach holds promise for a compelling value proposition by preserving kidney function and expediting patient recovery, ultimately reducing hospital stays and associated costs. Equipped with a proprietary specialized catheters and pump, the device optimizes kidney function during critical recovery periods, such as post-surgery. Currently, the JuxtaFlow RAD is under investigation and is not available for sale in any geography. About Roivios Roivios is a clinical-stage medical device company committed to pioneering solutions for kidney health. Our lead product, the JuxtaFlow Renal Assist Device (RAD), is designed to preserve kidney function and offer a proactive approach to managing kidney disease. We aim to demonstrate improved renal outcomes, potentially reducing the need for dialysis, and lowering healthcare costs. Holding proprietary patents in key kidney technologies, we aim to revolutionize kidney disease management. With plans to extend its application beyond kidney disease to various medical settings, Roivios is preparing for a transformative U.S. launch, aiming to redefine kidney disease management and improve patient quality of life. Discover more at roivios.com . This release contains forward-looking statements subject to risks and uncertainties. Actual results may differ significantly. Media Contact : Kelly Krueger , Krueger PR, kelly@kruegerpr.com View original content to download multimedia: https://www.prnewswire.com/news-releases/fda-grants-ide-approval-for-the-pivotal-trial-of-the-juxtaflow-renal-assist-device-rad-302336698.html SOURCE Roivios, ltd
Chargers will be without top RB Dobbins and could lean on QB Herbert against Falcons